Evidence map›Paper›PMID 38551064›Full record

Trial reportThe Journal of school health2024

Assessment of COVID-19 Messaging Strategies to Increase Testing for Students With Intellectual and Developmental Disabilities.

Tyler J Walsh, Luther G Kalb, Michael Gemmell, Jingxia Liu, Charlene A Caburnay, Christina A Gurnett, Jason G Newland, COMPASS‐T Study Group

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of school health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tyler J WalshDepartment of Pediatrics, Division of Pediatric Infectious Diseases, Washington University in St. Louis, 660 S Euclid Ave, St. Louis, 63110, MO, USA.ORCID 0009-0002-7704-6149
Luther G KalbKennedy Krieger Institute, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, 3901 Greenspring Ave, Baltimore, 21211, MD, USA.
Michael GemmellDepartment of Pediatrics, Division of Pediatric Infectious Diseases, Washington University in St. Louis, 660 S Euclid Ave, St. Louis, 63110, MO, USA.ORCID 0000-0003-3667-216X
Jingxia LiuDepartment of Surgery, Washington University in St. Louis, 4921 Parkview Pl, St. Louis, 63110, MO, USA.
Charlene A CaburnayBrown School of Social Work, Washington University in St. Louis, 6350 Forsyth Blvd, St. Louis, 63105, MO, USA.
Christina A GurnettDepartment of Neurology, Division of Pediatric and Developmental Neurology, Washington University in St. Louis, 660 S Euclid Ave, St. Louis, 63110, MO, USA.
Jason G NewlandDepartment of Pediatrics, Division of Pediatric Infectious Diseases, Washington University in St. Louis, 660 S Euclid Ave, St. Louis, 63110, MO, USA.
COMPASS‐T Study Group

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
WUIDDRC Supplement-Supporting the health and well-being of children with intellectual and developmental disability during COVID-19 pandemicP50HD103525 · NICHD · WASHINGTON UNIVERSITY · PI JEFFREY D MILBRANDT · 2020 to 2026
$15.5M
Sleep and Circadian Dysfunction, Brain and Neurobehavioral Development in AutismP50HD103538 · NICHD · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI Stewart H Mostofsky · 2020 to 2026
$9.9M
WUIDDRC and KKI Safe Return to SchoolOT2HD107556 · NICHD · WASHINGTON UNIVERSITY · PI GURNETT, CHRISTINA, KALB, LUTHER · 2021 to 2021
$2.7M
NCATS NIH HHS UL1 TR002345NCI NIH HHS P30 CA091842NICHD NIH HHS OT2 HD107556NICHD NIH HHS P50 HD103525NICHD NIH HHS P50 HD103538
6 · The paper itself

Abstract

backgroundStudents with intellectual and developmental disabilities (IDD) were disproportionately impacted by the COVID-19 pandemic. This study's goal was to assess the effectiveness of 2 messaging strategies on participation in SARS-CoV-2 weekly testing.

methodsCluster randomized trials were conducted at 2 school systems, the special school district (SSD) and Kennedy Krieger Institute (Kennedy) to assess messaging strategies, general versus enhanced, to increase weekly screening for SARS-CoV-2. Testing was offered to staff and students from November 23, 2020 to May 26, 2022. The primary outcomes were percentage of students and staff consented weekly and percentage of study participants who had a test performed weekly. Generalized estimating equation models were utilized to evaluate the primary outcomes.

resultsIncreases in enrollment and testing occurred during study start up, the beginning of school years, and following surges in both systems. No statistical difference was observed in the primary outcomes between schools receiving standard versus enhanced messaging. IMPLICATIONS FOR SCHOOL HEALTH POLICY, PRACTICE, AND EQUITY: Frequent and consistent communication is vital for families and staff. Weekly screening testing within schools is possible and highlighted the importance of utilizing equitable protocols to provide important testing to students with IDD.

conclusionEnhanced messaging strategies did not increase the number of participants enrolled or the percentage of enrolled participants being tested on a weekly basis.

Indexed as

COVID-19COVID-19 TestingDevelopmental DisabilitiesIntellectual DisabilityAdolescentChildFemaleHumansMaleMass ScreeningSARS-CoV-2School Health ServicesSchoolsStudentscommunication strategiesCOVID‐19infectious diseasesintellectual and developmental disabilitiespublic health

Identifiers

PMID38551064
PMCPMC11088980

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.